Keywords: ribozyme, repurchases, hcv, drug, rights, lilly, pharmaceuticals

Ribozyme repurchases HCV drug rights from Lilly

Article | 05 October 2000

Print This

Ribozyme Pharmaceuticals has repurchased the rights to itsanti-hepatitis C virus drug Heptazyme (LY466700) from Eli Lilly, and says it will ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in